Alopecia universalis congenita
MONDO:0008757The most severe form of alopecia areata, an inflammatory disease of the hair follicle, which is characterized by a complete loss of hair of the scalp and all the hair-bearing areas of the body.
Also known as: alopecia universalis congenita, atrichia, generalised, atrichia, generalized, ALUNC, AU, alopecia areata universalis, alopecia universalis
6 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a higher dose of this pill regrow hair in severe alopecia?
Disease control Recruiting nowThis study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a poop pill cure bald spots? new trial tests microbiota transplant for alopecia
Disease control Recruiting nowThis study tests whether transplanting healthy gut bacteria can help people with alopecia areata, an autoimmune disease that causes patchy or total hair loss. Forty adults with moderate to severe hair loss will take either antibiotic and microbiota transplant capsules or a placeb…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New study to settle debate: which drug works best for Kids' hair loss?
Disease control Recruiting nowThis study compares two common drugs, cyclosporine and methotrexate, to treat moderate-to-severe alopecia areata in children aged 2-17. The goal is to see which medicine helps regrow hair better over 9 months. Participants and their parents choose which treatment to try, and doct…
Phase: PHASE4 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Compassionate use of ritlecitinib offers hope for severe hair loss patients
Disease control AVAILABLEThis program provides early access to ritlecitinib for people with severe alopecia areata who have lost at least half of their scalp hair and have not responded to or cannot tolerate standard treatments. The goal is to offer a potential treatment option before the drug is fully a…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC